Your browser doesn't support javascript.
loading
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
Papamichael, Konstantinos; Afif, Waqqas; Drobne, David; Dubinsky, Marla C; Ferrante, Marc; Irving, Peter M; Kamperidis, Nikolaos; Kobayashi, Taku; Kotze, Paulo G; Lambert, Jo; Noor, Nurulamin M; Roblin, Xavier; Roda, Giulia; Vande Casteele, Niels; Yarur, Andres J; Arebi, Naila; Danese, Silvio; Paul, Stephane; Sandborn, William J; Vermeire, Séverine; Cheifetz, Adam S; Peyrin-Biroulet, Laurent.
Afiliación
  • Papamichael K; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: kpapamic@bidmc.harvard.edu.
  • Afif W; Department of Medicine, Division of Gastroenterology, McGill University Health Center, Montreal, QC, Canada.
  • Drobne D; Department of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
  • Dubinsky MC; Department of Pediatrics, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Ferrante M; KU Leuven, Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
  • Irving PM; Gastroenterology, Guy's and St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Kamperidis N; Department of IBD, St Mark's Hospital, Imperial College London, London, UK.
  • Kobayashi T; Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
  • Kotze PG; Catholic University of Paraná (PUCPR), Curitiba, Brazil.
  • Lambert J; Department of Head and Skin, Ghent University Hospital, Ghent, Belgium.
  • Noor NM; Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Roblin X; Department of Gastroenterology, University Hospital of Saint Etienne, Saint Etienne, France.
  • Roda G; IBD Center, Humanitas Clinical and Research Center-IRCCS, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Vande Casteele N; Department of Medicine, University of California San Diego, La Jolla, CA, USA.
  • Yarur AJ; Medical College of Wisconsin, Milwaukee, WI, USA.
  • Arebi N; Department of IBD, St Mark's Hospital, Imperial College London, London, UK.
  • Danese S; IBD Center, Humanitas Clinical and Research Center-IRCCS, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Paul S; Department of Gastroenterology, University Hospital of Saint Etienne, Saint Etienne, France.
  • Sandborn WJ; Department of Medicine, University of California San Diego, La Jolla, CA, USA.
  • Vermeire S; KU Leuven, Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
  • Cheifetz AS; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Peyrin-Biroulet L; Department of Gastroenterology, Nancy University Hospital, Nancy, France; INSERM U1256 NGERE, Lorraine University, Nancy, France.
Lancet Gastroenterol Hepatol ; 7(2): 171-185, 2022 02.
Article en En | MEDLINE | ID: mdl-35026171
Therapeutic drug monitoring (TDM) has emerged as a useful tool for optimising the use of biologics, and in particular anti-tumour necrosis factor (anti-TNF) therapy, in inflammatory bowel disease (IBD). However, challenges remain and are hindering the widespread implementation of TDM in clinical practice. These barriers include identification of the optimal drug concentration to target, the lag time between sampling and results, and the proper interpretation of anti-drug antibody titres among different assays. Solutions to overcome these barriers include the harmonisation of TDM assays and the use of point-of-care testing. Other unmet needs include well designed prospective studies and randomised controlled trials focusing on proactive TDM, particularly during induction therapy. Future studies should also investigate the utility of TDM for biologics other than anti-TNF therapies in both IBD and other immune-mediated inflammatory diseases such as rheumatoid arthritis and psoriasis, and the use of pharmacokinetic modelling dashboards and pharmacogenetics towards individual personalised medicine.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Productos Biológicos / Enfermedades Inflamatorias del Intestino / Monitoreo de Drogas Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Lancet Gastroenterol Hepatol Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Productos Biológicos / Enfermedades Inflamatorias del Intestino / Monitoreo de Drogas Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Lancet Gastroenterol Hepatol Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos